Page 62 - MEMOCiberesp014-ENG

RESEARCH GROUPS
Nanoparticle and Peptide Chemical Group
Programme: Nanomedicine
Lead Researcher: Albericio Palomera, Fernando Group Members
STAFF MEMBERS: Acosta Crespo, Gerardo Alexis | Farras Torres, Inmaculada | Pulido Martínez, Daniel ASSOCIATED MEMBERS: Álvarez Domingo, Mercedes | Blanco Canosa, Juan Bautista | Royo Expósito,
Miriam | Spengler, Jan | Tulla Puche, Judit
CONTRIBUTORS: López Ibáñez, Alba | Lorente Crivillé, Adriana | Melgarejo Díaz, Marta | Pulido Villamil, Ximena Carolina
Main lines of research
• •
•
• •
• •
• •
• • • •
Design and synthesis of bioactive low molecular weight compounds and peptides .
Dendrimers based on defined units of olidoethylene glycol (OEG) as multifunctional systems for the creation of new biomaterials with application to drug delivery and tissue engineering (osteogenesis) .
Drugs-polymer conjugates based on polyglutamic (PGA) or OEG dendrimers, as nanomedicine for the ad- vanced colorectal cancer treatment . Study of the use of these platforms on monotherapy and combined therapy .
Multiple ligands as chemical tools to study various biological processes, for example: G protein-coupled receptors (GPCRs) oligomerization .
Design and synthesis of a bicomponent thermoreversible hydrogel platform which combines the bioactive peptide dendrimer decorated hyaluronic acid with the thermoresponsive hyaluronic acid for developing sca- ffolds for tissue engineering with application to regenerative medicine (bone and cartilage regeneration) .
Development of protein drug delivery systems (PEGylation, peptide functionalized nanovesicles) for substitu- tive therapy (ie: Fabry disease) .
Design and synthesis of gamma peptides with capacity to cross biological barriers, such as the cytoplasmatic membrane of eukaryotic cells and parasites (Leishmania) and the blood brain barrier (BBB) .
Development of new target peptides for colorectal and triple negative breast cancer tissues .
Vectorized multicomponent nanoparticles as drug delivery systems and modulators of pharmacokinetic pro- perties .
Multimodal imaging agents (SPECT, OI, CT and MRI) . Nanoparticles for imaging diagnostic applications . Surface engineering for controlling cell proliferation on diverse materials . Development of solid phase methodology to synthesize biomolecules and other compounds . Bionanotechnologies as new strategy to save compounds that failed on clinical or preclinical phases .
62
CIBER-BBN » Annual report 2014